Biotech RadarJobs updated

COMPANY

Quralis Corporation

HQ: Cambridge, MA source · quralis.com ↗

Clinical Phase 1

Keywords: neurology amyotrophic lateral sclerosis QRL-101 QRL-201

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants source ↗
  2. Trial start Phase 1: A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants source ↗
  3. Trial start Phase 1: A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS source ↗
  4. Trial start Phase 1: A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants source ↗
  5. Trial start Phase 1: A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants source ↗
  6. Trial start Phase 1: A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants source ↗
  7. Trial start Phase 1: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS source ↗

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT07421778A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy ParticipantsPhase 1CompletedFeb 2, 2026Aug 31, 2026 (actual)
NCT05633459A Study Evaluating the Safety and Tolerability of QRL-201 in ALSPhase 1Active, not recruitingDec 16, 2022May 29, 2026 (estimated)
NCT06714396A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALSPhase 1CompletedNov 11, 2024Aug 22, 2025 (actual)
NCT06877624A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy ParticipantsPhase 1CompletedJan 10, 2025May 15, 2025 (actual)
NCT06681441A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy ParticipantsPhase 1CompletedOct 7, 2024Dec 24, 2024 (actual)
NCT06532396A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy ParticipantsPhase 1CompletedJul 1, 2024Dec 20, 2024 (actual)
NCT05667779A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy ParticipantsPhase 1CompletedDec 22, 2022Dec 27, 2023 (actual)
Feedback